The integration of Morris Plains-based KMK Consulting provides Tredence with two decades of experience in real-world evidence, commercial analytics, and market research. By layering Tredence’s agentic AI and data engineering platforms over KMK’s established domain expertise, the company plans to compress development timelines from initial R&D through to commercial launch. This strategy addresses a critical bottleneck in the pharmaceutical industry, where process-heavy workflows have historically resisted rapid digital transformation.
Beyond technical integration, the acquisition secures a stronger foothold in the Veeva ecosystem, the cloud-based CRM standard used by roughly 70% of global pharmaceutical firms. As agentic AI begins to commoditize general data services, Tredence CEO Shub Bhowmick emphasized that deep industry knowledge serves as the primary competitive moat. For KMK founder Michael Karbachinskiy, the partnership offers a vehicle to scale specialized scientific insights into actionable, large-scale decision intelligence. The move follows projections that the global market for AI in life sciences will climb to $69.3 billion by 2031, positioning Tredence to act as a primary partner for firms navigating the transition from traditional research to AI-driven commercialization.
Comments (0)
No comments yet. Be the first!